# Biological Treatment of Psoriasis—Data So Far

## TL;DR

This paper reviews the effectiveness of biologic drugs in treating psoriasis, a chronic skin disease, based on clinical trial data.

## Contribution

The paper provides a comprehensive evaluation and comparison of currently approved biologic treatments for psoriasis.

## Key findings

- Biologic agents have improved treatment efficacy for moderate-to-severe psoriasis.
- Clinical trial data shows the key features of approved biologic drugs for psoriasis.
- Long-term drug therapy is essential to manage symptoms and improve quality of life in psoriasis patients.

## Abstract

Psoriasis is a chronic, inflammatory skin disease occurring worldwide that significantly affects patients’ quality of life. This common skin condition is characterized by abnormal hyperplasia of keratinocytes, which leads to the formation of raised, scaly plaques, typically located on the head, elbows, knees, and lumbar region. Psoriasis usually requires long-term drug therapy, which aims not only to combat skin symptoms but also to improve quality of life. Although topical treatments, systemic treatments (methotrexate, cyclosporine, acitretin), and phototherapy play a role, biologic agents have improved the efficacy of treatment of moderate-to-severe psoriasis. The purpose of this article is to comprehensively review the clinical trial data and evaluate and compare the key features of the currently approved biologic drugs for the treatment of psoriasis.